• Facebook
  • Rss
  • Twitter
  • Youtube
  • Store
  • Donate
  • 0Shopping Cart
NCCS - National Coalition for Cancer Survivorship
  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • COVID-19 Resources for Cancer Survivors
    • Order Our Resources
  • News
    • Cancer Convos Podcast
  • Events
    • Ellen L. Stovall Award
      • 2020 Stovall Awards
      • Honorees
      • Sponsors
      • Committees
      • Reception
      • Nominations
    • Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us
  • Search
  • Menu Menu

Year-End MATCH (DEADLINE Dec 31): Donate & Make a Difference | Donate

20years

Guest Post by Dr. Melissa Hudson: How Has the Childhood Cancer Survivor Study Informed the Care of Children With Cancer?

August 31, 2015/in Cancer News, Cancer Policy Blog NCCS News /by actualize
The eighth principle in the Imperatives for Quality Cancer Care states, “Systematic long-term follow-up should generate data that contribute to improvements in cancer therapies and decreases in morbidity.” In this post, Dr. Melissa Hudson of St. Jude Children’s Hospital describes the multitude of ways in which the Childhood Cancer Survivor Study’s decades of medical data has helped connect the dots between primary childhood cancers and the late effects of associated treatments.

Melissa M. Hudson, MD

Guest Post By Melissa M. Hudson, MD
Director, Cancer Survivorship Division, Dept. of Oncology, St. Jude Children’s Research Hospital

Progress in survival for childhood malignancies is tempered by the sequelae of the cancer and its treatment. Compelling evidence supports that childhood cancer survivors are a highly vulnerable group with a substantial risk of adverse health-related and quality-of-life outcomes resulting from their curative cancer therapy, broadly called “late effects”. Observational studies of survivor health outcomes represent a critical first step to characterizing those at high risk for late effects who may benefit from interventions to prevent or reduce the risk of treatment-related health problems. This research involves investigations evaluating how the risk of a specific late effect is influenced by the primary cancer and its treatment, as well as by personal factors such as age, sex and race, and underlying genetic predisposition and health-related behaviors.

The Childhood Cancer Survivor Study (CCSS), a multi-institutional, multi-disciplinary collaborative NCI-funded research resource, was established in 1994 to systematically evaluate long-term outcomes among childhood cancer patients who survived five or more years from diagnosis. The CCSS cohort, which now includes more than 24,000 survivor participants diagnosed between 1970 and 1999, has been the source of some of the most significant publications addressing long-term mortality, morbidity and quality of life of childhood cancer survivors.

Seminal findings from this cohort include:

  • Documentation of the magnitude and severity of chronic health conditions experienced by survivors in the first three decades following treatment;[1][2]
  • Demonstration of increasing and excess late mortality attributed to subsequent neoplasms, cardiac, and pulmonary causes among exposed childhood cancer patients,[3] especially among survivors of Hodgkin lymphoma;[4]
  • Delineation of dose-risk models for radiation-associated breast cancer,[5][6] CNS tumors,[7] and thyroid cancer;[8]
  • Identification of increased risk of late-occurring and recurrent stroke among long-term survivors exposed to CNS radiation;[9][10]
  • Documentation of the impact of modifiable cardiovascular risk factors like hypertension on the incidence and severity of major cardiac events;[2]
  • Characterization of sociodemographic factors, cancer treatments and health behaviors predisposing to impairment in physical and psychological health status among aging childhood cancer survivors;[11]
  • Evaluation of the impact of cancer treatment on neurocognitive functioning, emotional health and distress and health-related quality of life;[12][13]
  • Identification of sub-optimal participation in screening and surveillance practices for subsequent neoplasms[14][15] and health-protective behaviors like physical activity.[16][17]

Findings from these studies have been essential in developing safer therapies for newly diagnosed patients, counseling patients and families about potential health risks, and guiding the development of health screening recommendations and health-preserving interventions both during and after completion of cancer therapy. As such, the CCSS resource has played a pivotal role in informing the care of children with cancer across the survivorship spectrum. Ongoing research in the cohort aims to characterize risk profiles for survivors from more modern eras (1987-1999) and integrate molecular biology-based approaches to refine to expand risk definitions for targeted survivorship outcomes that will enhance identification of high-risk populations who may benefit from measures to prevent and re-mediate cancer treatment toxicity.

About the Author
Melissa M. Hudson, MD is currently a Member and Director of the Cancer Survivorship Division in the Department of Oncology at St. Jude Children’s Research Hospital. She directs the After Completion of Therapy Clinic, which now monitors over 5,000 long-term childhood cancer survivors treated on St. Jude trials. Dr. Hudson serves as Co-Chair of the Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer and Co-Chair of the International Late Effects of Childhood Cancer Guideline Harmonization Group. She is also the Chair of the Childhood Cancer Survivor Study Education Committee.

The views & opinions expressed in any guest post featured on our site are those of the guest author and do not necessarily reflect the opinions & views of the National Coalition for Cancer Survivorship.
Read our blog and comment policies here.


Sources Cited

  1. Oeffinger et al, New England Journal of Medicine, 2006
  2. Armstrong et al, Journal of Clinical Oncology, 2014
  3. Mertens et al, Journal of the National Cancer Institute, 2008
  4. Castellino et al, Blood, 2011
  5. Inskip et al, JCO, 2009
  6. Moskowitz et al, JCO, 2014
  7. Neglia et al, JNCI
  8. Sigurdson et al, Lancet, 2005
  9. Bowers et al, JCO, 2006
  10. Fullerton et al, Neurology, 2015
  11. Hudson et al, JCO, 2014
  12. Gurney et al, JCO, 2009
  13. Kadan-Lottick et al, JNCI, 2010
  14. Oeffinger et al, JAMA, 2009
  15. Nathan et al, Ann Intern Med, 2010
  16. Wilson, C.L. et al, Cancer Epidemiology, Biomarkers, and Prevention, 2014
  17. Jones et al, JCO, 2014

Read more posts from our 20 Years Later: The Imperatives for Quality Cancer Care Blog Series »

 

Tags: 20 Years Later, cancer care, Cancer Survivorship, childhood cancer, Guest Post, quality
Share this entry
  • Share on Facebook
  • Share on Twitter
https://canceradvocacy.org/wp-content/uploads/2015/01/20years.gif 500 500 actualize https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png actualize2015-08-31 15:04:072020-10-21 15:17:58Guest Post by Dr. Melissa Hudson: How Has the Childhood Cancer Survivor Study Informed the Care of Children With Cancer?
You might also like
Fotolia 73341760 S CPAT Members’ Op-ed: ACA Replacement Must Include Affordable Insurance for Preexisting Conditions
20years NCCS CEO Shelley Fuld Nasso Introduces the Sixth Principle of the Imperatives for Quality Cancer Care
Cancer Moonshot Cancer Moonshot Blue Ribbon Panel Recommends Research to Minimize Debilitating Side Effects of Cancer Treatment
FacebookProfile3 Drug scarcity’s dire cost, and some ways to cope
NCCS Starburst 250px Second Anniversary of State Exchanges: Affordable Options for Cancer Patients, But the Devil Remains in the Details
journeyforwardthumb Journey Forward: How Can We Make Survivorship Care Planning a Reality?
NCCS Starburst 250px What Caught Our Eye: How the Senate Tax Bill Affects Health Care, Surgical Relief for Lymphedema, and An Investigation Into Exorbitant Costs of Care
NCCS Starburst 250px What Caught Our Eye: ACA Stabilization Waiting Game; Living with Lung Cancer; Cancer and Aging; Caregiving; The CancerSEEK Test; & More

Latest News

HHS Humphrey bldg 1200

NCCS, Cancer Groups Urge CMS to Withdraw Most Favored Nation (MFN) Medicare Part B Rule That Will Harm Patients and Reduce Access to Care

December 22, 2020
The National Coalition for Cancer Survivorship (NCCS) joined other member organizations…
Read more
https://canceradvocacy.org/wp-content/uploads/2017/10/HHS-Humphrey-bldg-1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2020-12-22 20:27:262021-01-04 21:38:15NCCS, Cancer Groups Urge CMS to Withdraw Most Favored Nation (MFN) Medicare Part B Rule That Will Harm Patients and Reduce Access to Care
NCCS Letter to HHS

NCCS Letter to HHS: Proposed Regulatory Review Rule Would Create Unnecessary Uncertainty for Patients

December 9, 2020
The National Coalition for Cancer Survivorship (NCCS) recently submitted comments…
Read more
https://canceradvocacy.org/wp-content/uploads/HHS-Humphrey-bldg-1200-1030x515-1.jpg 515 1030 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2020-12-09 17:30:502020-12-10 08:22:55NCCS Letter to HHS: Proposed Regulatory Review Rule Would Create Unnecessary Uncertainty for Patients
HHS Humphrey bldg 1200

NCCS Opposes Most Favored Nation (MFN) Rule: New Medicare Part B Drug Payment Model Will Harm Patients

December 3, 2020
The National Coalition for Cancer Survivorship (NCCS) opposes the Most Favored Nation…
Read more
https://canceradvocacy.org/wp-content/uploads/HHS-Humphrey-bldg-1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2020-12-03 21:26:462020-12-03 21:28:06NCCS Opposes Most Favored Nation (MFN) Rule: New Medicare Part B Drug Payment Model Will Harm Patients

Take Action

Stovall Award

The Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care is a unique opportunity for patients and survivors to recognize pioneers who are transforming the cancer care system.

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • COVID-19 Resources for Cancer Survivors
    • Order Our Resources
  • News
    • Cancer Convos Podcast
  • Events
    • Ellen L. Stovall Award
      • 2020 Stovall Awards
      • Honorees
      • Sponsors
      • Committees
      • Reception
      • Nominations
    • Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2021 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

WCOE: Poll Finds Women Think Mammograms Should Be Done Annually, Why Your Doctor... NCCS Starburst Thumbnail Snyder Video Post: Dr. Claire Snyder Discusses How Patient-Reported Outcomes Can Improve...
Scroll to top

Harmar Brereton, MD

Founder
Northeast Regional Cancer Institute

 

“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”

—Karen M. Saunders
President, Northeast Regional Cancer Institute